ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements

Comments
Loading...

ChromaDex Corp CDXC has announced a supply agreement with Designs for Health, a U.S.-based manufacturer of premium dietary supplements for healthcare practitioners (HCPs). 

  • ChromaDex's proprietary healthy aging ingredient Niagen will be added to multi-ingredient Designs for Health formulas. Click here to read more on Niagen.
  • The Company says that Niagen is the world's first and only FDA-safety reviewed and patented form of nicotinamide riboside.
  • The new products will be available exclusively through the Company's extensive HCP network.
  • The Niagen inclusive formulas will be available to healthcare practitioners through the Designs for Health customers throughout the U.S., Canada, and Australia.
  • In October, ChromaDex announced findings from a clinical study of Niagen ingredient (nicotinamide riboside, NR) in patients with ataxia-telangiectasia (AT).
  • AT is a rare, inherited neurodegenerative disorder characterized by premature aging, cerebellar degeneration, immunodeficiency, and cancer predisposition. 
  • The study found that supplementation with NR improved ataxia scores and increased immunoglobulins, or antibodies, in the immune-compromised patients under 18 years.
  • Price Action: CDXC shares are up 9.06% at $3.01 during the market session on the last check Thursday.
Overview Rating:
Speculative
50%
Technicals Analysis
100
0100
Financials Analysis
20
0100
Overview
Market News and Data brought to you by Benzinga APIs

Posted In:
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!